Using CITI Program Content: Good Clinical Practice (GCP)



Similar documents
Human Subjects Research (HSR) Series

Continuing Education Certified Courses

Policy on Human Subject Protection Training, Certification and Recertification at AUB

Good Clinical Practice 101: An Introduction

Responsible Conduct of Research (RCR)

History and Principles of Good Clinical Practice

A New View: How Frequently is GCP Training Needed and What Should Be Included? January 29, 2015

Adventist HealthCare, Inc.

BUILDING QUALITY INTO CLINICAL TRIALS AN FDA PERSPECTIVE

New Investigator Collaborations and Interactions: Regulatory

Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS

Presented by Rosemarie Bell 24 April 2014

INVESTIGATOR MANUAL. Table of Contents

CLINICAL TRIALS WITH MEDICINES IN EUROPE

Health Canada s GCP Compliance Program. GCP Information Sessions November 2010

The Beginner Research Assistant/Coordinator (CRC) Track Basic Level

2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials

Health Canada: Clinical Trial Inspection Planning. GCP Information Sessions November 2010

HP Software LICENSE KEY PROCESSES

Clinical Training Management

REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology)

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group

The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations

Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions

GCP - Records Managers Association

LIBRARY GUIDE: Clinical Medical Device

12.0 Investigator Responsibilities

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities

Comparing GCP Requirements for Medical Device Clinical Trials in the US and Japan

Collaborative Institutional Training Initiative (CITI)

CITI PROGRAM GCP TRAINING PROGRAM AND CITI PROGRAM LMS

Core Training Outline

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE]

Data Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Centralized vs Onsite Monitoring:

RAPS ONLINE UNIVERSITY

Overview. Health Science Authority. Implementation of ICH guideline in Singapore. Singapore s experience

Signature Requirements for the etmf

An Overview of Clinical Archiving. Russell Joyce Records & Information Manager

Patient Centric Monitoring Methodology

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to

UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM. DoD/DON-funded Research

LIBRARY GUIDE: Clinical Pharmaceutical

How to Run Clinical Trials in Private Practice

To Certify or Not to Certify

1

To Certify or Not to Certify Sandra Halvorson, BA, CCRP

How Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program

Clinical evaluation Latest development in expectations EU and USA

CLINICAL RESEARCH PROTOCOL CHECKLIST

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity

Workshop on Quality Risk Management Making Trials Fit for Purpose

OECD Recommendation on the Governance of Clinical Trials

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART

Good Documentation Practices

PREP Course #27: Medical Device Clinical Trial Management

CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS:

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide

TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP

Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA

Bachelor of Business Administration Program in Human Resource Management (International Program) Revised Curriculum, Academic Year 2013

Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA Phone:

Geoff Taylor Director, Clinical Quality Assurance, Eisai Product Creation Systems

Risk Based Approach to on site monitoring Do we need to check everything? Roger Newbery, VP Clinical Management EMEA, PPD

SCIENTIFIC SUBSTANTIATION OF STANDARD OPERATIONAL PROCEDURES ROLE IN QUALITY ASSURANCE SYSTEM IN CLINICAL DRUG TRIALS

Role of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.

Guide to CE Navigation and Frequently Asked Questions (FAQs)

STANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol

European Forum for Good Clinical Practice Audit Working Party

Annex A. Levels 1 5 of the Clinical Research Coordinator Track in the Clinical Research WSQ Framework

RISK-BASED MONITORING: THE GOOD, THE BAD AND THE UGLY

CTEP Workshop. An Overview of the NCI s Cancer Therapy and Evaluation Program (CTEP) CTEP s Mission. Workshop Objectives. NCI Organizational Structure

Quality Management in Clinical Trials

Roles & Responsibilities of the Sponsor

Data Management Unit Research Institute for Health Sciences, Chiang Mai University

CLINICAL RESEARCH ROLES CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES

A responsible approach to clinical trials. Bioethics in action

Clinical Research in Mauritius

Why Monitoring Is More Than Just SDV

Catherine Jahrsdorfer, RN, BSN Director of Clinical Services USF Health Office of Clinical Research

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE

This unit will provide the structure needed to achieve successful supervision and oversight of the study. We will explain the importance of an

Information Shield Solution Matrix for CIP Security Standards

OPER H6001. Pharmaceutical Operations Mgt. APPROVED. Pharmaceutical Operations Management for Engineers. Credits: 5. NFQ Level: 9

IMP management at site. Dmitry Semenyuta

US Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines

Vertex Investigator-Initiated Studies Program Overview

SECURITY AWARENESS TRAINING. July 2015

ICH Q10 Pharmaceutical Quality System (PQS)

Measurement and Criteria

Clinical Research Professional Certification & Preparing for the CCRP Exam

FDA Presentation - Society for Clinical Research Sites

Transcription:

CONTENT AUTHOR Jaime A. Arango, EdD, CIP CITI Program at the University of Miami INTRODUCTION Like all CITI Program educational materials, the components of the Good Clinical Practice (GCP) series can be customized to fit the specific needs of your organization s learners. Taking advantage of this flexibility requires that you are familiar with the GCP offerings and with the capabilities of the CITI Program s web platform to deliver them. This module addresses the components of the GCP series. For general information on the CITI Program s instructional capabilities, see Using CITI Program Content: An Introduction. LEARNING OBJECTIVES By the end of this module, you should be able to: Identify the structure of the CITI Program s GCP series. Understand the recommended configuration for GCP courses in light of industry standards. Obtain additional information on the GCP series from the GCP Catalog and Help Desk staff GCP SERIES The CITI Program s GCP series consists of three basic courses and one refresher course, each of which has been designed to meet the varying needs of organizations. Descriptions of these courses are provided below. * Indicates that this ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigational Site Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of GCP training among trial sponsors. Basic Courses GCP for Clinical Trials with Investigational Drugs and Medical Devices - U.S. FDA Focus* Intended for research personnel involved in drug, device, or biologic studies and who would benefit from a more U.S. FDA focused training. Page 1 of 6

GCP for Clinical Trials with Investigational Drugs and Biologics ICH Focus* Intended for investigators involved in drug and biologic studies where a more international focused training would be meaningful. A Spanish version of this course meeting TransCelerate BioPharma minimum criteria is also available. GCP for Clinical Trials with Investigational Medical Devices Intended for research personnel involved in device studies. It is more U.S. FDA focused and recognizes that the regulatory requirements for device studies have substantial differences in a number of areas from those related to drugs and biologics. This course also contains reference to appropriate ISO elements. Refresher Course GCP for Clinical Trials with Investigational Drugs and Biologics ICH Focus Refresher* Intended to reinforce the importance of concepts covered in the basic level GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus) course. SELECTING MODULES FOR YOUR ORGANIZATION S LEARNERS For GCP courses, the CITI Program offers the following options on how modules are presented to learners. Required: A module that must be taken by the learner in order to earn a Completion Report. Elective: A module that is associated with a set of other Elective modules. Learners select and complete a specified minimum number of electives from the set in order to earn a Completion Report. For example, if a course contains the requirement of completing six Elective modules, and ten choices are presented, the learner has to complete any six of the ten in order to move forward. Supplemental: A module that becomes available to the learner after the Required and Elective modules have been completed. A learner may review Supplemental modules on a voluntary basis. The selection of Required, Elective, and Supplemental is entirely up to the organization. Although, there must be at least one Required module for each learner group. It is important to note that organizations may also add additional modules to any course and may develop customized organization- specific content to supplement the training. Page 2 of 6

Basic Courses GCP for Clinical Trials with Investigational Drugs and Medical Devices U.S. FDA Focus Drugs and Medical Devices U.S. FDA Focus course, as well as recommendations / requirements for how they are presented. It is recommended (and required to meet TransCelerate minimum criteria) that the following modules be presented as Required: The CITI Good Clinical Practice Course for Clinical Trials Involving Drugs and Devices Overview of New Drug Development Overview of ICH GCP ICH Comparison Between ICH GCP E6 and U.S. FDA Regulations Conducting Investigator- Initiated Studies According to FDA Regulations and GCP Investigator Obligations in FDA- Regulated Clinical Research Managing Investigational Agents According to GCP Requirements Overview of U.S. FDA Regulations for Medical Devices Informed Consent in Clinical Trials of Drugs, Biologics, and Devices Detecting and Evaluating Adverse Events Reporting Serious Adverse Events Monitoring of Clinical Trials by Industry Sponsors Audits and Inspections of Clinical Trials Completing the CITI GCP Course The following Supplemental modules may be beneficial to this GCP course: Humanitarian Use Devices (HUDs) Phase I Research: Understanding Phase I Research Phase I Research: Protecting Phase I Subjects GCP for Clinical Trials with Investigational Drugs and Biologics ICH Focus Drugs and Biologics ICH Focus course, as well as recommendations / requirements for how they are presented. It is recommended (and required to meet TransCelerate minimum criteria) that the following modules be presented as Required: The CITI Good Clinical Practice Course for Clinical Trials Involving Drugs and Biologics Overview of New Drug Development Page 3 of 6

Overview of ICH GCP ICH Comparison Between ICH GCP E6 and U.S. FDA Regulations Conducting Investigator- Initiated Studies According to FDA Regulations and GCP Investigator Obligations in FDA- Regulated Research Managing Investigational Agents According to GCP Requirements Informed Consent in Clinical Trials of Drugs and Biologics Monitoring Clinical Trials of Drugs by Industry Sponsors Audits and Inspections of Clinical Trials of Drugs and Biologics Detecting and Evaluating Adverse Events Reporting Serious Adverse Events in Investigations of Drugs and Biologics Completing the CITI GCP Course The following Supplemental modules may be beneficial to this GCP course: Phase I Research: Understanding Phase I Research Phase I Research: Protecting Phase I Subjects GCP for Clinical Trials with Investigational Medical Devices Medical Devices course, as well as recommendations for how they are presented. It is recommended that the following modules be presented as Required: The CITI Good Clinical Practice Course for Clinical Trials Involving Investigational Medical Devices Overview of U.S. FDA Regulations for Medical Devices Investigator Obligations in FDA- Regulated Clinical Research of Devices Conducting Investigator- Initiated Clinical Trials of Devices Managing Investigational Devices According to GCP Requirements Informed Consent in Clinical Trials of Devices Monitoring Clinical Trials of Devices Audits and Inspections of Clinical Trials of Devices Reporting Requirements for Device Studies Completing the CITI GCP Course The following Supplemental module may be beneficial to this GCP course: Humanitarian Use Devices (HUDs) Phase I Research: Understanding Phase I Research Phase I Research: Protecting Phase I Subjects Page 4 of 6

Refresher Course GCP for Clinical Trials with Investigational Drugs and Biologics ICH Focus Refresher Drugs and Biologics ICH Focus Refresher course, as well as recommendations / requirements for how they are presented. It is recommended (and required to meet TransCelerate minimum criteria) that the following modules be presented as Required: International Conference on Harmonisation (ICH): GCP Requirements Investigator s Responsibilities and GCP Informed Consent Safety Management Investigational Product (Drug) Management Audits, Inspection, and Monitoring of Drug Studies Sponsor Responsibilities and GCP SUPPLEMENTING GCP COURSES In order to meet the needs of subscribing organizations, the CITI Program can assist administrators in creating courses that best meet their needs, including combining modules* from across the CITI Program. To discuss course recommendations that combine modules from different CITI Program offerings, please contact the CITI Program Help Desk at (305) 243-7970. *Courses intended to present the principles of GCP must include all of the GCP modules within one of the CITI Program's GCP offerings. RETRAINING FREQUENCY There is not a uniform standard regarding how frequently GCP training should occur. For a retraining (refresher) cycle, organizations should designate the frequency of GCP retraining for each selected course. In 2015, the CITI Program released the GCP for Clinical Trials with Investigational Drugs and Biologics ICH Focus Refresher, which is a dedicated refresher for the basic ICH focus course. For all other GCP courses, organizations should have learners complete the entire basic course again as their refresher. TRAINING METHODS There is not a uniform standard regarding the methods and format used for GCP training. For many organizations, the CITI Program courses provide the majority of GCP training. For other Page 5 of 6

organizations, the CITI Program s courses are presented in conjunction with organization- specific content. The CITI Program s flexibility allows organizations multiple means of training users. LANGUAGE AVAILABILITY At the present time, the CITI Program s entire GCP series is available in English. A select number of modules are also available in Spanish, Portuguese, Korean, Chinese, Thai, French, and African French. See the GCP catalog for more details regarding language availability. CONTINUING EDUCATION (CME/CE) CREDITS Detailed information regarding CME/CE credits is available in the GCP catalog or CE Resources. SUMMARY The CITI Program s GCP series is highly customizable and commonly used to help meet organizational training requirements. Many organizational administrators have found it helpful to visit the CITI Program s website at least annually to review current course offerings and to consider these in light of the organization s previously selected options. The CITI Program s Help Desk is experienced with all of its curricular series, including GCP, and can assist you in configuring content for your learners. Contact them at citisupport@med.miami.edu or (305) 243-7970. ACKNOWLEDGEMENTS Sally Mann, Reid Cushman, Daniel Smith, and other members of the CITI Program provided advice and content for this module. Original Release: September 2013 Last Updated: June 2015 Page 6 of 6